Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition)

Breast Cancer China Anti-Cancer Association The Society of; of the Oncology Branch of the Chinese Medical Association Breast Oncology Group

doi:10.19401/j.cnki.1007-3639.2023.12.004

您当前的位置：

首页 >

文章列表页 >

Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition)

Guideline and Concensus | 更新时间：2025-12-31

- Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition)
- China Oncology Vol. 33, Issue 12, Pages: 1092-1187(2023)
- 作者机构：
- 作者简介：
  
  SHAO Zhimin.
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.12.004
  CLC： R737.9
- Received：15 November 2023，
  
  Revised：2023-11-30，
  
  Published：30 December 2023
- 稿件说明：
移动端阅览
Breast Cancer China Anti-Cancer Association The Society of, of the Oncology Branch of the Chinese Medical Association Breast Oncology Group. Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition)[J]. China Oncology, 2023, 33(12): 1092-1187.
DOI：

Breast Cancer China Anti-Cancer Association The Society of, of the Oncology Branch of the Chinese Medical Association Breast Oncology Group. Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition)[J]. China Oncology, 2023, 33(12): 1092-1187. DOI： 10.19401/j.cnki.1007-3639.2023.12.004.

摘要

世界卫生组织（World Health Organization，WHO）国际癌症研究机构最新发布的数据显示，乳腺癌现已成为全球发病率最高的恶性肿瘤，严重危害广大女性的身心健康。中国抗癌协会乳腺癌专业委员会2007年首次制订《中国抗癌协会乳腺癌诊治指南与规范（2007版）》以来共更新8版，指南一直与时俱进，兼顾证据的权威性、知识的前沿性和在广大基层医疗机构的适用性。本次制订的《中国抗癌协会乳腺癌诊治指南与规范（2024年版）》在2021年版的基础上进行了相应的更新，纳入了乳腺癌诊断和分类的新理念、精准治疗的新工具、手术操作的新规范和综合治疗的新方案，旨在为乳腺癌防控及诊治领域的医务工作者提供指导和依据。

Abstract

According to the latest data released by the International Agency for Research on Cancer of the World Health Organization (WHO)

breast cancer has become the malignant tumor with the highest incidence rate around the world

seriously endangering the physical and mental health of women. Since the Society of Breast Cancer China Anti-Cancer Association firstly formulated “guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2007 edition)” in 2007

a total of 8 editions have been updated. The guidelines have been keeping pace with the times

taking into account the authority of evidence

the cutting-edge knowledge and the practicality in the vast grassroots. The “guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2024 edition)” has been updated on the basis of the 2021 Edition

incorporating new concepts of breast cancer diagnosis and classification

new methods for precision treatment

new specifications for surgical procedures and new plans for comprehensive treatment

aiming to provide guidance and basis for medical staff in the field of breast cancer prevention

control

diagnosis and treatment.

关键词

Keywords

references

WHO Classification of Tumours Editorial Board . Breast tumours [M ] . 5th ed. Lyon : International Agency for Research on Cancer , 2019 .

NCCN Clinical Prac tice Guideline in Oncology TM . Breast Cancer. 2014 National Comprehensive Cancer Network [EB/OL ] . https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category=1 & id=1419 https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category=1&id=1419 https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category=1&id=1419 [2021-09-02 ] .

American Joint Committee on Cancer . AJCC cancer staging handbook [M ] . 7th ed. Chicago : Springer , 2010 .

BUCHHOLZ T A , SOMERFIELD M R , GRIGGS J J , et al . Margins for breast-conserving surgery with whole-breast irradiation in stage Ⅰ and Ⅱ invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline [J ] . J Clin Oncol , 2014 , 32 ( 14 ): 1502 - 1506 . DOI: 10.1200/JCO.2014.55.1572 http://doi.org/10.1200/JCO.2014.55.1572 https://ascopubs.org/doi/10.1200/JCO.2014.55.1572 https://ascopubs.org/doi/10.1200/JCO.2014.55.1572

KUNKLER I H , WILLIAMS L J , JACK W J , et al . Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME Ⅱ): a randomised controlled trial [J ] . Lancet Oncol , 2015 , 16 ( 3 ): 266 - 273 . DOI: 10.1016/S1470-2045(14)71221-5 http://doi.org/10.1016/S1470-2045(14)71221-5 https://linkinghub.elsevier.com/retrieve/pii/S1470204514712215 https://linkinghub.elsevier.com/retrieve/pii/S1470204514712215

GIULIANO A E , MCCALL L , BEITSCH P , et al . Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial [J ] . Ann Surg , 2010 , 252 ( 3 ): 426 - 432 ; discussion 432 - 433 . DOI: 10.1097/SLA.0b013e3181f08f32 http://doi.org/10.1097/SLA.0b013e3181f08f32

DONKER M , VAN TIENHOVEN G , STRAVER M E , et al . Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial [J ] . Lancet Oncol , 2014 , 15 ( 12 ): 1303 - 1310 . DOI: 10.1016/S1470-2045(14)70460-7 http://doi.org/10.1016/S1470-2045(14)70460-7

MORAN M S , SCHNITT S J , GIULIANO A E , et al . Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages Ⅰ and Ⅱ invasive breast cancer [J ] . J Clin Oncol , 2014 , 32 ( 14 ): 1507 - 1515 . DOI: 10.1200/JCO.2013.53.3935 http://doi.org/10.1200/JCO.2013.53.3935 https://ascopubs.org/doi/10.1200/JCO.2013.53.3935 https://ascopubs.org/doi/10.1200/JCO.2013.53.3935

EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP EBCTCG . Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J ] . Lancet Oncol , 2018 , 19 ( 1 ): 27 - 39 . DOI: S1470-2045(17)30777-5 http://doi.org/S1470-2045(17)30777-5

GIANNI L , PIENKOWSKI T , IM Y H , et al . 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J ] . Lancet Oncol , 2016 , 17 ( 6 ): 791 - 800 . DOI: S1470-2045(16)00163-7 http://doi.org/S1470-2045(16)00163-7

SIKOV W M , BERRY D A , PEROU C M , et al . Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603 (Alliance) [J ] . J Clin Oncol , 2015 , 33 ( 1 ): 13 - 21 .

ADAMS S , LOI S , TOPPMEYER D , et al . Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase Ⅱ KEYNOTE-086 study [J ] . Ann Oncol , 2019 , 30 ( 3 ): 405 - 411 . DOI: 10.1093/annonc/mdy518 http://doi.org/10.1093/annonc/mdy518 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310762 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310762

ADAMS S , SCHMID P , RUGO H S , et al . Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase Ⅱ KEYNOTE-086 study [J ] . Ann Oncol , 2019 , 30 ( 3 ): 397 - 404 . DOI: 10.1093/annonc/mdy517 http://doi.org/10.1093/annonc/mdy517 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310750 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310750

GOETZ M P , TOI M , CAMPONE M , et al . MONARCH 3: abemaciclib as initial therapy for advanced breast cancer [J ] . J Clin Oncol , 2017 , 35 ( 32 ): 3638 - 3646 . DOI: 10.1200/JCO.2017.75.6155 http://doi.org/10.1200/JCO.2017.75.6155

ROBSON M , IM S A , SENKUS E , et al . Olaparib for metastatic breast cancer in patients with a germline BRCA mutation [J ] . N Engl J Med , 2017 , 377 ( 6 ): 523 - 533 . DOI: 10.1056/NEJMoa1706450 http://doi.org/10.1056/NEJMoa1706450 http://www.nejm.org/doi/10.1056/NEJMoa1706450 http://www.nejm.org/doi/10.1056/NEJMoa1706450

SLEDGE G W Jr , TOI M , NEVEN P , et al . MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy [J ] . J Clin Oncol , 2017 , 35 ( 25 ): 2875 - 2884 . DOI: 10.1200/JCO.2017.73.7585 http://doi.org/10.1200/JCO.2017.73.7585

SCHMID P , ADAMS S , RUGO H S , et al . Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer [J ] . N Engl J Med , 2018 , 379 ( 22 ): 2108 - 2121 . DOI: 10.1056/NEJMoa1809615 http://doi.org/10.1056/NEJMoa1809615 http://www.nejm.org/doi/10.1056/NEJMoa1809615 http://www.nejm.org/doi/10.1056/NEJMoa1809615

TRIPATHY D , IM S A , COLLEONI M , et al . Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial [J ] . Lancet Oncol , 2018 , 19 ( 7 ): 904 - 915 . DOI: S1470-2045(18)30292-4 http://doi.org/S1470-2045(18)30292-4

TURNER N C , SLAMON D J , RO J , et al . Overall survival with palbociclib and fulvestrant in advanced breast cancer [J ] . N Engl J Med , 2018 , 379 ( 20 ): 1926 - 1936 . DOI: 10.1056/NEJMoa1810527 http://doi.org/10.1056/NEJMoa1810527 http://www.nejm.org/doi/10.1056/NEJMoa1810527 http://www.nejm.org/doi/10.1056/NEJMoa1810527

BLOK E J , KROEP J R , MEERSHOEK-KLEIN KRANENBARG E , et al . Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05) [J ] . J Natl Cancer Inst , 2018 , 110 ( 1 ).

BURSTEIN H J , LACCHETTI C , ANDERSON H , et al . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update [J ] . J Clin Oncol , 2019 , 37 ( 5 ): 423 - 438 . DOI: 10.1200/JCO.18.01160 http://doi.org/10.1200/JCO.18.01160

FRANCIS P A , PAGANI O , FLEMING G F , et al . Tailoring adjuvant endocrine therapy for premenopausal breast cancer [J ] . N Engl J Med , 2018 , 379 ( 2 ): 122 - 137 . DOI: 10.1056/NEJMoa1803164 http://doi.org/10.1056/NEJMoa1803164 http://www.nejm.org/doi/10.1056/NEJMoa1803164 http://www.nejm.org/doi/10.1056/NEJMoa1803164

GNANT M , MLINERITSCH B , STOEGER H , et al . Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group trial 12 [J ] . Ann Oncol , 2015 , 26 ( 2 ): 313 - 320 . DOI: 10.1093/annonc/mdu544 http://doi.org/10.1093/annonc/mdu544

MAMOUNAS E P , BANDOS H , LEMBERSKY B C , et al . Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial [J ] . Lancet Oncol , 2019 , 20 ( 1 ): 88 - 99 . DOI: S1470-2045(18)30621-1 http://doi.org/S1470-2045(18)30621-1

METZGER FILHO O , GIOBBIE-HURDER A , MALLON E , et al . Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial [J ] . J Clin Oncol , 2015 , 33 ( 25 ): 2772 - 2779 . DOI: 10.1200/JCO.2015.60.8133 http://doi.org/10.1200/JCO.2015.60.8133

PAN H C , GRAY R , BRAYBROOKE J , et al . 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years [J ] . N Engl J Med , 2017 , 377 ( 19 ): 1836 - 1846 . DOI: 10.1056/NEJMoa1701830 http://doi.org/10.1056/NEJMoa1701830 http://www.nejm.org/doi/10.1056/NEJMoa1701830 http://www.nejm.org/doi/10.1056/NEJMoa1701830

BLUM J L , FLYNN P J , YOTHERS G , et al . Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG oncology) [J ] . J Clin Oncol , 2017 , 35 ( 23 ): 2647 - 2655 . DOI: 10.1200/JCO.2016.71.4147 http://doi.org/10.1200/JCO.2016.71.4147

CARDOSO F , VAN'T VEER L J , BOGAERTS J , et al . 70-gene signature as an aid to treatment decisions in early-stage breast cancer [J ] . N Engl J Med , 2016 , 375 ( 8 ): 717 - 729 . DOI: 10.1056/NEJMoa1602253 http://doi.org/10.1056/NEJMoa1602253 http://www.nejm.org/doi/10.1056/NEJMoa1602253 http://www.nejm.org/doi/10.1056/NEJMoa1602253

EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP EBCTCG . Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials [J ] . Lancet , 2015 , 386 ( 10001 ): 1353 - 1361 . DOI: S0140-6736(15)60908-4 http://doi.org/S0140-6736(15)60908-4

EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP EBCTCG . Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials [J ] . Lancet , 2019 , 393 ( 10179 ): 1440 - 1452 . DOI: 10.1016/S0140-6736(18)33137-4 http://doi.org/10.1016/S0140-6736(18)33137-4 https://linkinghub.elsevier.com/retrieve/pii/S0140673618331374 https://linkinghub.elsevier.com/retrieve/pii/S0140673618331374

LOIBL S , WEBER K E , TIMMS K M , et al . Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto [J ] . Ann Oncol , 2018 , 29 ( 12 ): 2341 - 2347 . DOI: S0923-7534(19)34246-2 http://doi.org/S0923-7534(19)34246-2

MASUDA N , LEE S J , OHTANI S , et al . Adjuvant capecitabine for breast cancer after preoperative chemotherapy [J ] . N Engl J Med , 2017 , 376 ( 22 ): 2147 - 2159 . DOI: 10.1056/NEJMoa1612645 http://doi.org/10.1056/NEJMoa1612645 http://www.nejm.org/doi/10.1056/NEJMoa1612645 http://www.nejm.org/doi/10.1056/NEJMoa1612645

MOORE H C , UNGER J M , PHILLIPS K A , et al . Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy [J ] . N Engl J Med , 2015 , 372 ( 10 ): 923 - 932 . DOI: 10.1056/NEJMoa1413204 http://doi.org/10.1056/NEJMoa1413204 http://www.nejm.org/doi/10.1056/NEJMoa1413204 http://www.nejm.org/doi/10.1056/NEJMoa1413204

NITZ U , GLUZ O , CLEMENS M , et al . West German study PlanB trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer [J ] . J Clin Oncol , 2019 , 37 ( 10 ): 799 - 808 . DOI: 10.1200/JCO.18.00028 http://doi.org/10.1200/JCO.18.00028

SPARANO J A , GRAY R J , MAKOWER D F , et al . Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer [J ] . N Engl J Med , 2018 , 379 ( 2 ): 111 - 121 . DOI: 10.1056/NEJMoa1804710 http://doi.org/10.1056/NEJMoa1804710 http://www.nejm.org/doi/10.1056/NEJMoa1804710 http://www.nejm.org/doi/10.1056/NEJMoa1804710

PROWELL T M , BEAVER J A , PAZDUR R . Residual disease after neoadjuvant therapy - developing drugs for high-risk early breast cancer [J ] . N Engl J Med , 2019 , 380 ( 7 ): 612 - 615 . DOI: 10.1056/NEJMp1900079 http://doi.org/10.1056/NEJMp1900079 http://www.nejm.org/doi/10.1056/NEJMp1900079 http://www.nejm.org/doi/10.1056/NEJMp1900079

SPARANO J A , GRAY R J , RAVDIN P M , et al . Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer [J ] . N Engl J Med , 2019 , 380 ( 25 ): 2395 - 2405 . DOI: 10.1056/NEJMoa1904819 http://doi.org/10.1056/NEJMoa1904819 http://www.nejm.org/doi/10.1056/NEJMoa1904819 http://www.nejm.org/doi/10.1056/NEJMoa1904819

EARL H M , HILLER L , VALLIER A L , et al . 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial [J ] . Lancet , 2019 , 393 ( 10191 ): 2599 - 2612 . DOI: S0140-6736(19)30650-6 http://doi.org/S0140-6736(19)30650-6

MARTIN M , HOLMES F A , EJLERTSEN B , et al . Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial [J ] . Lancet Oncol , 2017 , 18 ( 12 ): 1688 - 1700 . DOI: S1470-2045(17)30717-9 http://doi.org/S1470-2045(17)30717-9

VON MINCKWITZ G , HUANG C S , MANO M S , et al . Trastuzumab emtansine for residual invasive HER2-positive breast cancer [J ] . N Engl J Med , 2019 , 380 ( 7 ): 617 - 628 . DOI: 10.1056/NEJMoa1814017 http://doi.org/10.1056/NEJMoa1814017 http://www.nejm.org/doi/10.1056/NEJMoa1814017 http://www.nejm.org/doi/10.1056/NEJMoa1814017

VON MINCKWITZ G , PROCTER M , DE AZAMBUJA E , et al . Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer [J ] . N Engl J Med , 2017 , 377 ( 2 ): 122 - 131 . DOI: 10.1056/NEJMoa1703643 http://doi.org/10.1056/NEJMoa1703643 http://www.nejm.org/doi/10.1056/NEJMoa1703643 http://www.nejm.org/doi/10.1056/NEJMoa1703643

GIANNI L , PIENKOWSKI T , IM Y H , et al . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J ] . Lancet Oncol , 2012 , 13 ( 1 ): 25 - 32 . DOI: 10.1016/S1470-2045(11)70336-9 http://doi.org/10.1016/S1470-2045(11)70336-9

MA F , LI Q , CHEN S S , et al . Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer [J ] . J Clin Oncol , 2017 , 35 ( 27 ): 3105 - 3112 . DOI: 10.1200/JCO.2016.69.6179 http://doi.org/10.1200/JCO.2016.69.6179

LANG G T , JIANG Y Z , SHI J X , et al . Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing [J ] . Nat Commun , 2020 , 11 ( 1 ): 5679 . DOI: 10.1038/s41467-020-19342-3 http://doi.org/10.1038/s41467-020-19342-3

JIANG Y Z , MA D , SUO C , et al . Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies [J ] . Cancer Cell , 2019 , 35 ( 3 ): 428 - 440 .e5. DOI: 10.1016/j.ccell.2019.02.001 http://doi.org/10.1016/j.ccell.2019.02.001 https://linkinghub.elsevier.com/retrieve/pii/S1535610819300960 https://linkinghub.elsevier.com/retrieve/pii/S1535610819300960

LI J J , YU K D , PANG D , et al . Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase Ⅲ trial [J ] . J Clin Oncol , 2020 , 38 ( 16 ): 1774 - 1784 . DOI: 10.1200/JCO.19.02474 http://doi.org/10.1200/JCO.19.02474 https://ascopubs.org/doi/10.1200/JCO.19.02474 https://ascopubs.org/doi/10.1200/JCO.19.02474

YU K D , YE F G , HE M , et al . Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial [J ] . JAMA Oncol , 2020 , 6 ( 9 ): 1390 - 1396 . DOI: 10.1001/jamaoncol.2020.2965 http://doi.org/10.1001/jamaoncol.2020.2965 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769305 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769305

WANG X , WANG S S , HUANG H , et al . Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial [J ] . JAMA , 2021 , 325 ( 1 ): 50 - 58 . DOI: 10.1001/jama.2020.23370 http://doi.org/10.1001/jama.2020.23370 https://jamanetwork.com/journals/jama/fullarticle/2774295 https://jamanetwork.com/journals/jama/fullarticle/2774295

HU X C , ZHANG J , XU B H , et al . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial [J ] . Lancet Oncol , 2015 , 16 ( 4 ): 436 - 446 . DOI: 10.1016/S1470-2045(15)70064-1 http://doi.org/10.1016/S1470-2045(15)70064-1 https://linkinghub.elsevier.com/retrieve/pii/S1470204515700641 https://linkinghub.elsevier.com/retrieve/pii/S1470204515700641

ZHANG J , LIN Y , SUN X J , et al . Biomarker assessment of the CBCSG006 trial: a randomized phase Ⅲ trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer [J ] . Ann Oncol , 2018 , 29 ( 8 ): 1741 - 1747 . DOI: 10.1093/annonc/mdy209 http://doi.org/10.1093/annonc/mdy209 https://linkinghub.elsevier.com/retrieve/pii/S0923753419341286 https://linkinghub.elsevier.com/retrieve/pii/S0923753419341286

LIN M X , CHEN Y , JIN Y Z , et al . Comparative overall survival of CDK4/6 inhibitors plus endocrine therapy vs endocrine therapy alone for hormone receptor-positive, HER2-negative metastatic breast cancer [J ] . J Cancer , 2020 , 11 ( 24 ): 7127 - 7136 . DOI: 10.7150/jca.48944 http://doi.org/10.7150/jca.48944 https://www.jcancer.org/v11p7127.htm https://www.jcancer.org/v11p7127.htm

FALLON M , GIUSTI R , AIELLI F , et al . Management of cancer pain in adult patients: ESMO clinical practice guidelines [J ] . Ann Oncol , 2018 , 29 ( Suppl 4 ): iv166 -iv191. DOI: 10.1093/annonc/mdy152 http://doi.org/10.1093/annonc/mdy152 https://linkinghub.elsevier.com/retrieve/pii/S0923753419316989 https://linkinghub.elsevier.com/retrieve/pii/S0923753419316989

ZHAO S , MA D , XIAO Y , et al . Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance [J ] . Oncologist , 2020 , 25 ( 10 ): e1481 -e1491. DOI: 10.1634/theoncologist.2019-0982 http://doi.org/10.1634/theoncologist.2019-0982 https://academic.oup.com/oncolo/article/25/10/e1481/6443719 https://academic.oup.com/oncolo/article/25/10/e1481/6443719

JIANG Y Z , LIU Y , XIAO Y , et al . Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial [J ] . Cell Res , 2021 , 31 ( 2 ): 178 - 186 . DOI: 10.1038/s41422-020-0375-9 http://doi.org/10.1038/s41422-020-0375-9

ALBABTAIN H , ALWHAIBI M , ALBURAIKAN K , et al . Quality of life and complementary and alternative medicine use among women with breast cancer [J ] . Saudi Pharm J , 2018 , 26 ( 3 ): 416 - 421 . DOI: 10.1016/j.jsps.2017.12.020 http://doi.org/10.1016/j.jsps.2017.12.020

林洪生 , 刘杰 , 张英 . 《恶性肿瘤中医诊疗指南》的内涵及其意义 [J ] . 中国肿瘤临床与康复 , 2016 , 23 ( 3 ): 257 - 260 .

LIN H S , LIU J , ZHANG Y . Connotation and significance of “Guidelines for Diagnosis and Treatment of Malignant Tumors in Traditional Chinese Medicine” [J ] . Chin J Clin Oncol Rehabil , 2016 , 23 ( 3 ): 257 - 260 .

陈前军 , 裴晓华 . 早期乳腺癌中医辨证内治专家共识 [J ] . 现代中医临床 , 2020 , 27 ( 3 ): 5 - 8 .

CHEN Q J , PEI X H . Consensus on TCM syndrome differentiation and internal therapy for early-stage breast cancer [J ] . Mod Chin Clin Med , 2020 , 27 ( 3 ): 5 - 8 .

杨雯靖 , 念家云 , 杨国旺 . 中西医结合治疗乳腺癌现状及展望 [J ] . 北京中医药 , 2020 , 39 ( 10 ): 1009 - 1013 .

YANG W J , NIAN J Y , YANG G W . Present situation and prospect of treating breast cancer with integrated traditional Chinese and western medicine [J ] . Beijing J Tradit Chin Med , 2020 , 39 ( 10 ): 1009 - 1013 .

马瑞 , 张丹 , 林从尧 . 小金丸、逍遥丸及乳癖散结胶囊治疗乳腺增生的临床观察 [J ] . 现代中西医结合杂志 , 2015 , 24 ( 2 ): 140 - 142 .

MA R , ZHANG D , LIN C Y . Clinical observation of Koganemaru, Xiaoyao Pill and Rubisanjie Capsule in the treatment of mammary hyperplasia [J ] . Mod J Integr Tradit Chin West Med , 2015 , 24 ( 2 ): 140 - 142 .

《乳腺癌HER检测指南版》编写组 . 《乳腺癌HER2检测指南(2019版)》 [J ] . 中华病理学杂志 , 2019 , 48 ( 3 ): 169 - 175 .

HER2 Detection Guidline for Breast Cancer (2019 Edition) Writing Group . HER2 guideline for breast cancer (2019 Edition) [J ] . Chin J Pathol , 2019 , 48 ( 3 ): 169 - 175 .

《乳腺癌新辅助治疗的病理诊断专家共识2020版》编写组 . 乳腺癌新辅助治疗的病理诊断专家共识(2020版) [J ] . 中华病理学杂志 , 2020 , 49 ( 4 ): 296 - 304 .

Expert Consensus on Pathological Diagnosis of Neoadjuvant Therapy for Breast Cancer (2020 Edition) Writing Group . Writing Group. Expert consensus on pathological diagnosis of neoadjuvant therapy for breast cancer (2020 Edition) [J ] . Chin J Pathol , 2020 , 49 ( 4 ): 296 - 304 .

《乳腺癌雌、孕激素受体检测指南》编写组 . 乳腺癌雌、孕激素受体检测指南 [J ] . 中华病理学杂志 , 2015 , 44 ( 4 ): 237 - 240 .

Guidelines for Detection of Estrogen and Progesterone Receptors in Breast Cancer Writing Group . Guidelines for detection of estrogen and progesterone receptors in breast cancer [J ] . Chin J Pathol , 2015 , 44 ( 4 ): 237 - 240 .

GOLDHIRSCH A , INGLE J N , GELBER R D , et al . Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 [J ] . Ann Oncol , 2009 , 20 ( 8 ): 1319 - 1329 . DOI: 10.1093/annonc/mdp322 http://doi.org/10.1093/annonc/mdp322

GOLDHIRSCH A , WOOD W C , COATES A S , et al . Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011 [J ] . Ann Oncol , 2011 , 22 ( 8 ): 1736 - 1747 . DOI: 10.1093/annonc/mdr304 http://doi.org/10.1093/annonc/mdr304 https://linkinghub.elsevier.com/retrieve/pii/S0923753419384145 https://linkinghub.elsevier.com/retrieve/pii/S0923753419384145

GOLDHIRSCH A , WINER E P , COATES A S , et al . Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2013 [J ] . Ann Oncol , 2013 , 24 ( 9 ): 2206 - 2223 . DOI: 10.1093/annonc/mdt303 http://doi.org/10.1093/annonc/mdt303

WRIGHT M J , PARK J , FEY J V , et al . Perpendicular inked versus tangential shaved margins in breast-conserving surgery: does the method matter? [J ] . J Am Coll Surg , 2007 , 204 ( 4 ): 541 - 549 . DOI: 10.1016/j.jamcollsurg.2007.01.031 http://doi.org/10.1016/j.jamcollsurg.2007.01.031 https://journals.lww.com/00019464-200704000-00003 https://journals.lww.com/00019464-200704000-00003

ELSTON C W , ELLIS I O . Pathological prognostic factors in breast cancer.Ⅰ. The value of histological grade in breast cancer: experience from a large study with long-term follow-up [J ] . Histopathology , 2002 , 41 ( 3a ): 154 - 161 . DOI: 10.1046/j.1365-2559.2002.14892.x http://doi.org/10.1046/j.1365-2559.2002.14892.x https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2559.2002.14892.x https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2559.2002.14892.x

FRIERSON H F Jr , WOLBER R A , BEREAN K W , et al . Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma [J ] . Am J Clin Pathol , 1995 , 103 ( 2 ): 195 - 198 . DOI: 10.1093/ajcp/103.2.195 http://doi.org/10.1093/ajcp/103.2.195

HAMMOND M E , HAYES D F , DOWSETT M , et al . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [J ] . Arch Pathol Lab Med , 2010 , 134 ( 6 ): 907 - 922 . DOI: 10.1043/1543-2165-134.6.907 http://doi.org/10.1043/1543-2165-134.6.907

DOWSETT M , NIELSEN T O , A’HERN R , et al . Assessment of Ki-67 in breast cancer: recommendations from the international Ki-67 in breast cancer working group [J ] . J Natl Cancer Inst , 2011 , 103 ( 22 ): 1656 - 1664 . DOI: 10.1093/jnci/djr393 http://doi.org/10.1093/jnci/djr393 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djr393 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djr393

WOLFF A C , HAMMOND M E , HICKS D G , et al . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update [J ] . J Clin Oncol , 2013 , 31 ( 31 ): 3997 - 4013 . DOI: 10.1200/JCO.2013.50.9984 http://doi.org/10.1200/JCO.2013.50.9984

SYMMANS W F , PEINTINGER F , HATZIS C , et al . Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy [J ] . J Clin Oncol , 2007 , 25 ( 28 ): 4414 - 4422 . DOI: 10.1200/JCO.2007.10.6823 http://doi.org/10.1200/JCO.2007.10.6823

OGSTON K N , MILLER I D , PAYNE S , et al . A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival [J ] . Breast , 2003 , 12 ( 5 ): 320 - 327 . DOI: 10.1016/s0960-9776(03)00106-1 http://doi.org/10.1016/s0960-9776(03)00106-1

水若鸿 , 杨文涛 . 乳腺癌Ki-67阳性指数的检测和评估 [J ] . 中华病理学杂志 , 2013 , 42 ( 6 ): 420 - 423 .

SHUI R H , YANG W T . Detection and evaluation of Ki-67 positive index in breast cancer [J ] . Chin J Pathol , 2013 , 42 ( 6 ): 420 - 423 .

LIN M X , JIN Y Z , YANG Z Y , et al . Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer [J ] . Ther Adv Med Oncol , 2021 , 13 : 17588359211022881.

ZHANG J F , LIN M X , JIN Y Z , et al . Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia [J ] . Breast Cancer Res Treat , 2020 , 182 ( 3 ): 719 - 726 . DOI: 10.1007/s10549-020-05730-2 http://doi.org/10.1007/s10549-020-05730-2

《肿瘤病理诊断规范》项目组 . 肿瘤病理诊断规范(乳腺癌) [J ] . 中华病理学杂志 2016 , 45 ( 8 ): 525 - 528 .

The project team of Tumor Pathological Diagnosis Standard . Diagnostic criteria for tumor pathology (breast cancer) [J ] . Chin J Pathol , 2016 , 45 ( 8 ): 525 - 528 .

《中国乳腺导管原位癌病理诊断共识2022版》编写组 . 中国乳腺导管原位癌病理诊断共识(2022版) [J ] . 中华病理学杂志 , 2022 , 51 ( 9 ): 812 - 818 .

The Writing Team of the Chinese Consensus on Pathological Diagnosis of Breast Ductal Carcinoma in situ (2022 Edition) . Chinese consensus on pathological diagnosis of ductal carcinoma in situ of the breast (2022 edition) [J ] . Chin J Pathol , 2022 , 51 ( 9 ): 812 - 818 .

杨昭志 , 孟晋 , 马金利 , 等 . 早期乳腺癌术后靶区勾画共识 [J ] . 中国癌症杂志 , 2019 , 29 ( 9 ): 753 - 760 .

YANG Z Z , MENG J , MA J L , et al . Early stage breast cancer postoperative target volume contouring [J ] . China Oncol , 2019 , 29 ( 9 ) 753 - 760

WOLFF A C , ELIZABETH HALE HAMMOND M , ALLISON K H , et al . Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update [J ] . J Clin Oncol , 2018 , 36 ( 20 ): 2105 - 2122 . DOI: 10.1200/JCO.2018.77.8738 http://doi.org/10.1200/JCO.2018.77.8738

WOLFF A C , SOMERFIELD M R , DOWSETT M , et al . Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update [J ] . J Clin Oncol , 2023 , 41 ( 22 ): 3867 - 3872 . DOI: 10.1200/JCO.22.02864 http://doi.org/10.1200/JCO.22.02864 https://ascopubs.org/doi/10.1200/JCO.22.02864 https://ascopubs.org/doi/10.1200/JCO.22.02864

TARANTINO P , VIALE G , PRESS M F , et al . ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer [J ] . Ann Oncol , 2023 , 34 ( 8 ): 645 - 659 . DOI: 10.1016/j.annonc.2023.05.008 http://doi.org/10.1016/j.annonc.2023.05.008

SHI F , LIANG Z , ZHANG Q , et al . The performance of one-step nucleic acid amplification assay for intraoperative detection of sentinel lymph node macrometastasis in breast cancer: an updated meta-analysis [J ] . Breast , 2018 , 39 : 39 - 45 . DOI: S0960-9776(18)30053-5 http://doi.org/S0960-9776(18)30053-5

HUXLEY N , JONES-HUGHES T , COELHO H , et al . Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer [J ] . Health Technol Assess , 2015 , 19 ( 2 ): Ⅴ - ⅩⅩⅤ .

BUNDRED J R , MICHAEL S , STUART B , et al . Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis [J ] . BMJ , 2022 , 378 : e070346 .

中国抗癌协会乳腺癌专业委员会 . 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J ] . 中国癌症杂志 , 2021 , 31 ( 10 ): 954 - 1040 .

The Society of Breast Cancer China Anti-Cancer Association . Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2021 edition) [J ] . China Oncol , 2021 , 31 ( 10 ): 954 - 1040 .

Views

34546

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasms (2025 edition)

China Anti-Cancer Association guideline for diagnosis and treatment of cancer of multiple and unknown primaries (2023 edition)

China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)

Exploration of the efficacy and safety of indocyanine green in the evaluation and localization of breast cancer surgical margins: a single-center, observational cohort study

Related Author

The Society of Breast Cancer China Anti-Cancer Association

Breast Oncology Group of the Oncology Branch of the Chinese Medical Association

of Neuroendocrine Neoplasm of China Anti-Cancer Association Society

Society of Cancer of Multiple and Unknown Primary of China Anti-Cancer Association Yuguang

of Neuroendocrine Neoplasm of China Anti-Cancer Association Society

Gang LÜ

Guangqing WANG

Yan ZHENG

Related Institution

Department of Thyroid and Breast Surgery, The Fourth Affiliated Hospital of Anhui Medical University (Affiliated Chaohu Hospital)

Pathology Department, The Fourth Affiliated Hospital of Anhui Medical University (Affiliated Chaohu Hospital)

General Practice, Hefei First People’s Hospital

Department of Nuclear Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine

Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University

AI问答

⁰